+49(0)2233 923749 contact@klaasconsulting.com

References

Check the overview of our client portfolio

Client portfolio

{

TSLTissue Science Laboratories plc, UK

… You are a consummate professional, and I would have no hesitation in working with you again or recommending you to my colleagues… You delivered the project on time and within budget and assuming it all goes well will have significantly contributed to the future of TSL …
(TSLTissue Science Laboratories plc, UK)

{

CathRx Ltd., Australia

… I was delighted with the professional and immediate response from Klaas Consulting … From the initial briefing, through identifying and filtering a number of potential partners, to recommending a final number of candidates for meetings: every step was completed on schedule, with clear analysis of the potentials versus the original brief …

{

Toray Industries, Inc., Japan

… In every case, preferable result was provided within a time frame agreed in advance … Reports are well prepared and skillfully written to meet the client purpose and cover the points which should be addressed by the research …

{

GMD Generic Medical Devices Europe sa/nv, Belgium

… From our first contact till the end of this project, you have proven to have the right contacts, that you are organized and that you are very professional …

{

ACON Laboratories, Inc., USA

… I have known other consultants with talent equivalent to Klaas Consulting. Many of them lacked Maria Klaas good nature and humility and few demonstrated the genuine intellectual curiosity that Maria has continuously exhibited – a curiosity that is often accompanied by her excitement or enthusiasm for an idea, a market research, negotiation skills or the lead role in a challenging operatic performance of a company…

{

Gaymar Industries, Inc., USA

… Your report met the objectives. It was clear, concise, and provided detailed reimbursements information that we had not been able to obtain in the past …

Meet us in Duesseldorf or virtually 15-18 Nov. 21

Medica 2021 Duesseldorf

Latest Insights

  • Swissmedic refers to a leaflet on the obligations for authorised representatives, importers and distributors
  • European industry association for digital assistive technology DATEurope founded in early 2021. DAT includes aids for communication, for the blind and visually impaired, for environmental control, assistive call systems, software tools and robotics.
  • New web portal for the list of medical aids according to §139 SGB V of the GKV-Spitzenverband: for reference and online application
  • Revised guidance on "Designation of a Swiss authorised representative under the new MepV" of 29 January 2021, addressed to Swiss distributors and importers.
  • Overview of all assessments of new examination and treatment methods (NUB) by the G-BA
  • 22 Notified Bodies are now accredited. Currently (August 21) there are 4 in Italy, 2 in Finland, 3 in the Netherlands and 6 in Germany; in addition, one each in Slovakia, Hungary, Norway, France, Sweden, Ireland and Croatia. Nando database
  • the MHRA in the UK has published a guidance document for manufacturers and distributors of medical devices
  • BfArM included the first “apps on prescription” in the new directory for digital health applications (DiGA) in early October 2020
  • new standalone UKCA mark after Brexit; current EU CE marking will still be in operation for Medical Devices and invitro diagnostic in Great Britain until June 2023
  • EU-implementation regulation for the reprocessing of disposable products, valid from 26 May 2021
  • FDA increases medical device registration fees from October 2020
  • The European Commission published the new “Clinical evaluation assessment report template” of the Medical Devices Coordination Group (MDCG) on 17 July 2020
  • On 1 July 20, the Swiss Federal Council adopted the revision of the Regulation on Medical Devices (MepV) and the new Regulation on Clinical Trials for Medical Devices (KlinV-Mep). As a result, Switzerland remains subject to EU medical device law.
  • In-vitro-diagsnostics must be re-evaluated according to the new IVDR by 26 May 2022.
  • In future, the IVDR will also cover high-risk products that are manufactured and used in a single health facility, as well as genetic screening and tests for predisposing patients
  • The European Council postpones the application of EUDAMED by two years until May 2022